Drug
ECC4703
ECC4703 is a pharmaceutical drug with 4 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
2(50%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
1
25%
Ph phase_2
2
50%
Ph early_phase_1
1
25%
Phase Distribution
2
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Early Phase 1First-in-human
1(25.0%)
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(3)
Completed(1)
Detailed Status
Completed1
Not yet recruiting1
Recruiting1
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Early Phase 11 (25.0%)
Phase 11 (25.0%)
Phase 22 (50.0%)
Trials by Status
completed125%
not_yet_recruiting125%
recruiting125%
active_not_recruiting125%
Recent Activity
2 active trials
Showing 4 of 4
not_yet_recruitingphase_1
Study of ECC4703 With Sulfasalazine and Pitavastatin
NCT07726368
recruitingphase_2
A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
NCT07288138
active_not_recruitingphase_2
MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial
NCT07505303
completedearly_phase_1
FTIH of ECC4703 in Healthy Volunteers
NCT05552274
Clinical Trials (4)
Showing 4 of 4 trials
NCT07726368Phase 1
Study of ECC4703 With Sulfasalazine and Pitavastatin
NCT07288138Phase 2
A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
NCT07505303Phase 2
MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial
NCT05552274Early Phase 1
FTIH of ECC4703 in Healthy Volunteers
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4